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TO THE EDITOR
Atopic dermatitis (AD) is associated
with intense pruritus, high rates of sleep
disturbance (Silverberg et al., 2015b),
stigma, increased healthcare costs
(Silverberg, 2015) and poor quality of
life (Silverberg et al., 2015b). All of these
might contribute toward higher rates
of depression. Previous studies found
that Taiwanese adolescents/adults with
AD have a higher incidence of major
depressive disorder than those without
AD (1.42 vs. 0.20 per 1,000 person-
years) (Cheng et al., 2015), as well as a
higher prevalence of depression in
Korean males (10.4 vs. 5.3%) (Kim
et al., 2015). A recent study found
that US children with AD had signiﬁ-
cantly higher prevalences of ever having
depression (6.5%) and current depress-
ion (3.9%) compared with those without
AD (3.4% and 1.8%, respectively)
(Yaghmaie et al., 2013). However, the
prevalence of depression in US adults
with AD is not known.
We studied participants from the
2005–2006 NHANES and 2012 National
Health Interview Survey. Both surveys
were sponsored and conducted by
National Center for Health Statistics
(NCHS) of Centers for Disease Control
and Prevention. Households were
selected through a stratiﬁed, randomized,
multistage, and probability-cluster design.
Health interviews were conducted in the
home in either English or Spanish. The
survey results were weighted to represent
the population of non-institutionalized
adults nationally and in each state using
data from the U.S. Bureau of the Census,
and to account for the complex survey
design, survey non-response and post-
stratiﬁcation. This study was approved
by the institutional review board at the
Northwestern University.
The questions used to assess for history
of eczema and depression are shown
in Supplementary Table 1 online. In
NHANES, respondents were asked ques-
tions from the Patient Health Question-
naire (PHQ), a validated self-reported
assessment based on the nine DSM-IV
symptoms for depression (Spitzer et al.,
1999; Arroll et al., 2010). A binary
variable was also created based on the
SIGECAPS criteria (acronym for depres-
sion symptoms), which are predictive of
major depressive disorder when ⩾4/8
positive responses are combined with
depressed mood for at least two week
(Carlat, 1998). PHQ scores were classi-
ﬁed as none (score 0–4), mild (score 5–9),
moderate (score 10–14), and severe
(score 15–27) depression.
All data processing and statistical
analyzes were performed with SURVEY
procedures in SAS version 9.4 (SAS
Institute, Cary, NC). Complete data
analysis was performed. Associations
between AD and depression were
tested via logistic regression models.
In NHANES, the dependent variables
included the nine PHQ9 questions,
SIGECAPS, and total PHQ9 depression
score. In NHIS, the dependents vari-
ables were self-reported history of
depression ever or in the past year.
The independent variable was history of
AD. Multivariate models included age,
gender, race/ethnicity, level of educa-
tion, family poverty income ratio,
history of asthma and hay fever. Crude
and adjusted prevalence odds ratios
(OR) and 95% conﬁdence intervals
(CIs) were estimated.
A total of 5,555 adults (⩾18 years)
were included in NHANES 2005–2006.
The prevalence of AD was 6.2%
(95% CI: 5.6–6.8%). AD was associated
with female gender, poverty income
ratio ⩾ 4, greater than high school or
GED equivalent education, history of
asthma and hay fever (Supplementary
Table 2 online). One hundred and
nine adults (31.0%) with AD reported
one or more symptoms of depression. In
multivariate survey logistic regression
models of NHANES data that controlled
for socio-demographics, history of
asthma and hay fever, AD was asso-
ciated with higher odds of having little
interest in doing things, feeling down,
depressed or hopeless, feeling tired or
having little energy, having a poor
appetite, feeling bad themselves, having
trouble concentrating and moving
or speaking slowly or too fast and
having thoughts of being better off dead
(Table 1).
The prevalence of depression as
judged by the SIGECAPS criteria was
higher in adults with AD compared
with adults who did not have eczema
(17.5 vs. 10.5%; adjusted OR (95% CI):
1.89 (1.28–2.77)). Moreover, AD was
associated with higher odds of moder-
ate (2.24 (1.20–4.17)) and severe (5.64
(2.88–11.07)) depression as judged by
the PHQ9 score.
A total of 34,613 adults were inclu-
ded in NHIS 2012. The US prevalence
(95% CI) of eczema in adults was 7.2%
(6.9–7.6%). The associations of adult
eczema in NHIS 2012 were previously
described (Silverberg et al., 2015b).
The lifetime prevalence of health-
care diagnosed depression was higher
in adults with AD compared with
adults who did not have AD (26.9 vs.
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13.1%; adjusted OR (95% CI): 2.29
(2.02–2.61) (Table 2). In addition, AD
was associated with higher odds of
depression in the past year (2.31
(2.00–2.66)). There were no signiﬁcant
statistical interactions between history
of AD and other covariates as predictors
of depression.
These results conﬁrm and expand on
previous international studies that have
found a higher rates of depression among
adults with AD (Gupta and Gupta, 1998;
Cheng et al., 2015; Kim et al., 2015). We
were unable to assess the direction of
association between AD and depression;
however, it is likely bidirectional. That is,
AD increases the risk for depression (Gupta
and Gupta, 1998; Cheng et al., 2015; Kim
et al., 2015), whereas stress may trigger AD
(Oh et al., 2010). Either way, the results of
the present study and prior studies suggest
that adults with AD are at higher risk
for depression and would beneﬁt from
increased screening for depression.
This study has several strengths,
including similar results using two large-
scale, randomly sampled, diverse data-
bases using sampling weights that allow
for generalizability to the entire adult US
population. PHQ9 and SIGECAPS are
extensively validated screening question-
naires for depression. We previously
performed a multicenter validation
study and found that the question used
in NHANES for eczema has excellent
sensitivity, speciﬁcity, positive and nega-
tive predictive values (Silverberg et al.,
2015a). Previous studies also found good
concordance between self-reported
eczema and AD diagnosed by medical
examination (Susitaival et al., 1995; Flohr
et al., 2009). However, the question used
in NHIS did not specify healthcare-
diagnosed AD, which may decrease its
speciﬁcity. It is possible that some of the
higher rates of depression observed
in NHIS may be attributable to other
inﬂammatory skin disorders. However,
the similar prevalences of depression in
the past year in NHIS and SIGECAPS in
NHANES suggest that the higher preva-
lence observed are in fact from depres-
sion. We were able to control for many
potentially confounding factors in multi-
variate regression models. This study also
has several limitations. Questions per-
taining to history of depression in NHIS
were based on self-report and not
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conﬁrmed clinically through physician
report or billing. However, the similarity
between prevalence estimates from self-
report of healthcare diagnosis in NHIS
and SIGECAPS in NHANES suggests the
results of both studies are valid.
In conclusion, approximately one in
three US adults with AD reported any
symptoms of depression and one in three
adults with AD met diagnostic criteria for
major depressive disorder. Future research
is needed to determine whether improved
treatment of AD might prevent or mitigate
depressive symptoms in adults.
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Variable
Eczema
No Yes
Freq Percent (95% CI) Freq Percent (95% CI) Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Ever history of depression
No 27,412 86.9 (86.4–87.3) 1,745 73.1 (70.8–75.4) 1.00 — 1.00 —
Yes 4,671 13.1 (12.7–13.6) 741 26.9 (24.6–29.2) 2.44 (2.15–2.76) o0.0001 2.29 (2.02–2.61) o0.0001
1-year history of depression
No 28,750 90.7 (90.3–91.1) 1,923 80.1 (78.0–82.1) 1.00 — 1.00 —
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Binary survey logistic regression models were constructed with ever and 1-year history of depression as the binary dependent variables and history of eczema
as the independent variable. Multivariate models included age, gender, race/ethnicity, education, poverty income ratio, history of hay fever and asthma as the
dependent variables. Crude and adjusted prevalence ORs and 95% CIs were estimated.
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